192 related articles for article (PubMed ID: 9855637)
21. Mibefradil (Ro 40-5967) inhibits several Ca2+ and K+ currents in human fusion-competent myoblasts.
Liu JH; Bijlenga P; Occhiodoro T; Fischer-Lougheed J; Bader CR; Bernheim L
Br J Pharmacol; 1999 Jan; 126(1):245-50. PubMed ID: 10051142
[TBL] [Abstract][Full Text] [Related]
22. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Noll G; Lüscher TF
Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
[TBL] [Abstract][Full Text] [Related]
23. Properties of T-type calcium current in enkephalinergic neurones in guinea-pig hypothalamic slices.
Niespodziany I; Derambure P; Poulain P
Pflugers Arch; 1999 May; 437(6):871-80. PubMed ID: 10370065
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.
Triggle DJ
Am J Cardiol; 1996 Nov; 78(9A):7-12. PubMed ID: 8903279
[TBL] [Abstract][Full Text] [Related]
25. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker.
Clozel JP; Ertel EA; Ertel SI
J Hypertens Suppl; 1997 Dec; 15(5):S17-25. PubMed ID: 9481612
[TBL] [Abstract][Full Text] [Related]
26. Mibefradil-induced inhibition of proliferation of human peripheral blood mononuclear cells.
Lijnen P; Fagard R; Petrov V
J Cardiovasc Pharmacol; 1999 Apr; 33(4):595-604. PubMed ID: 10218730
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of T-type and L-type calcium channels by mibefradil: physiologic and pharmacologic bases of cardiovascular effects.
Leuranguer V; Mangoni ME; Nargeot J; Richard S
J Cardiovasc Pharmacol; 2001 Jun; 37(6):649-61. PubMed ID: 11392461
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibition of T-type Ca2+ channels by Ro 40-5967.
Mishra SK; Hermsmeyer K
Circ Res; 1994 Jul; 75(1):144-8. PubMed ID: 8013072
[TBL] [Abstract][Full Text] [Related]
29. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
Sarsero D; Fujiwara T; Molenaar P; Angus JA
Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
[TBL] [Abstract][Full Text] [Related]
30. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
31. Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise.
Muller CA; Opie LH; McCarthy J; Hofmann D; Pineda CA; Peisach M
J Am Coll Cardiol; 1998 Jul; 32(1):268-74. PubMed ID: 9669280
[TBL] [Abstract][Full Text] [Related]
32. Mibefradil block of cloned T-type calcium channels.
Martin RL; Lee JH; Cribbs LL; Perez-Reyes E; Hanck DA
J Pharmacol Exp Ther; 2000 Oct; 295(1):302-8. PubMed ID: 10991994
[TBL] [Abstract][Full Text] [Related]
33. Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels.
Romey G; Lazdunski M
J Pharmacol Exp Ther; 1994 Dec; 271(3):1348-52. PubMed ID: 7996445
[TBL] [Abstract][Full Text] [Related]
34. The block of the expressed L-type calcium channel is modulated by the beta 3 subunit.
Lacinová L; Ludwig A; Bosse E; Flockerzi V; Hofmann F
FEBS Lett; 1995 Oct; 373(2):103-7. PubMed ID: 7589444
[TBL] [Abstract][Full Text] [Related]
35. Role of sympathetic nerves in the differential effects of T-type and L-type calcium channel blockers on renin secretion and renin gene expression.
Hinder M; Wagner C; Krämer BK; Kurtz A
Nephrol Dial Transplant; 1999; 14 Suppl 4():44-5. PubMed ID: 10463214
[No Abstract] [Full Text] [Related]
36. Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA.
McDonough SI; Lampe RA; Keith RA; Bean BP
Mol Pharmacol; 1997 Dec; 52(6):1095-104. PubMed ID: 9415720
[TBL] [Abstract][Full Text] [Related]
37. Mibefradil potently blocks ATP-activated K(+) channels in adrenal cells.
Gomora JC; Enyeart JA; Enyeart JJ
Mol Pharmacol; 1999 Dec; 56(6):1192-7. PubMed ID: 10570046
[TBL] [Abstract][Full Text] [Related]
38. The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels.
Triggle DJ
Am J Hypertens; 1998 Apr; 11(4 Pt 3):80S-87S. PubMed ID: 9607371
[TBL] [Abstract][Full Text] [Related]
39. T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats.
Wagner C; Krämer BK; Hinder M; Kieninger M; Kurtz A
Br J Pharmacol; 1998 Jun; 124(3):579-85. PubMed ID: 9647484
[TBL] [Abstract][Full Text] [Related]
40. Effects of Ca2+ channel blockers on Ca2+ loading induced by metabolic inhibition and hyperkalemia in cardiomyocytes.
Tang T; Duffield R; Ho AK
Eur J Pharmacol; 1998 Nov; 360(2-3):205-11. PubMed ID: 9851587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
